Morphine extended release - AbbVie
Alternative Names: KADIAN; KAPANOLLatest Information Update: 28 Jun 2024
At a glance
- Originator Faulding Laboratories
- Developer Alpharma; Faulding Laboratories
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyspnoea; Pain
- Registered Opioid-related disorders
Most Recent Events
- 03 Jun 2024 Swissmedic, the national authorisation and supervisory authority for drugs and medical products approves morphine sulfate pentahydrate 10 mg and 200 mg capsule for Opioid-related disorders in Opioid-related disorders
- 27 Jan 2022 Mayne Pharma International terminates a phase-III pRESTO trial as study was unable to proceed per protocol due to COVID-19 precautions, in Opioid-related disorders in Canada (PO) (NCT03948464)
- 08 May 2020 Allergan has been acquired and merged into AbbVie